Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

(03) 9028 2888

clients@freshequities.com

Invion Limited

Investor presentation - Invion Limited

ASX:IVX

Invion Limited

Health

Invion Limited (IVX) is a clinical-stage drug development company in the biotechnology and pharmaceutical industry in Australia. IVX has three key development programs: INV102 for inflammatory respiratory disease; INV104, a leukotriene receptor antagonist; and, INV103, a modified, naturally occurring human protein. Former Names Cbio Limited (CBZ), 04/09/2012.

Read more

Market Cap

$49.84m

Price at Close

$0.009

4w avg. Volume

1.03m

4w avg. Turnover

$10.18k

Announcements
announcementt+2 movementdate
  • Becoming a substantial holder

    Shareholder Details

  • -

    17 Jan 2021

-

17 Jan 2021
  • Change in substantial holding

    Shareholder Details

  • -

    17 Jan 2021

-

17 Jan 2021
  • Change of Auditors

    Company Administration

  • 0.00%

    12 Jan 2021

0.00%

12 Jan 2021
  • Statement 708A Cleansing Statement

    Issued Capital

  • +10.00%

    23 Dec 2020

+10.00%

23 Dec 2020
  • Change of Director's Interest Notice - Rob Merriel

    Shareholder Details

  • +10.00%

    23 Dec 2020

+10.00%

23 Dec 2020
  • Appendix 2A

    Issued Capital

  • +10.00%

    23 Dec 2020

+10.00%

23 Dec 2020
  • Change of Director's Interest Notice - Thian Chew

    Shareholder Details

  • 0.00%

    14 Dec 2020

0.00%

14 Dec 2020
  • Change of Director's Interest Notice - Rob Merriel

    Shareholder Details

  • 0.00%

    14 Dec 2020

0.00%

14 Dec 2020
  • Change of Director's Interest Notice - Alan Yamashita

    Shareholder Details

  • 0.00%

    14 Dec 2020

0.00%

14 Dec 2020
  • Appendix 3G

    Issued Capital

  • 0.00%

    14 Dec 2020

0.00%

14 Dec 2020
Market Data

Current Price

$0.009

52WK HIGH

$0.013

52WK LOW

$0.006

1YR RETURN

-25.00%

1YR RETURN VS. SECTOR

-62.50%

90 DAY RETURN

-18.18%

ASX RANK

1,172

/2,047

SECTOR RANK

104

/168

SHARES OUTSTANDING

5.54b
ASX:IVX

Invion Limited

Health

Invion Limited (IVX) is a clinical-stage drug development company in the biotechnology and pharmaceutical industry in Australia. IVX has three key development programs: INV102 for inflammatory respiratory disease; INV104, a leukotriene receptor antagonist; and, INV103, a modified, naturally occurring human protein. Former Names Cbio Limited (CBZ), 04/09/2012.

Read more

Market Cap

$49.84m

Price at Close

$0.009

4w avg. Volume

1.03m

4w avg. Turnover

$10.18k

ASX:IVX is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.